Lexicon Pharmaceuticals targets a turnaround with sotagliflozin, LX9851, pilavapadin, and partnerships offering multiple ...
Sotagliflozin won't die, and in the absence of a marketing partner, management is committed to pursuing FDA approval for the heart failure indication on their own. Upcoming studies of rival drugs ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback